First quarter loss puts Cogent Biosciences stock in focus

Cogent Biosciences (COGT) is back on investor radars after reporting a first quarter net loss of US$97.35 million for the period ended March 31, 2026, compared with US$71.99 million a year earlier.

The latest quarter's larger loss comes after a year where total shareholder return was very large at over 7x. The share price return year to date of 5.73% and 30 day share price return of 4.32% suggest momentum has cooled but not reversed.

If the reaction to Cogent Biosciences has you reassessing opportunities in healthcare, it could be a good moment to broaden your search with 33 healthcare AI stocks

With the stock up strongly over the past year and trading at US$36.73, yet still sitting below the average analyst price target of about US$54.17, you have to ask: is there real upside left here, or is the market already pricing in future growth?

Preferred Price-to-Book of 11.5x: Is it justified?

Cogent Biosciences trades on a P/B of 11.5x, which sits below its peer average of 24.6x, yet well above the broader US Biotechs industry average of 2.3x.

P/B compares the stock price with the company’s net assets per share, so it is often used for asset light, early stage or loss making biotechs where earnings are not yet a useful anchor. For a clinical stage company with no meaningful revenue and ongoing losses, investors are effectively using P/B as a shorthand for how much promise they are willing to pay for in the development pipeline.

The numbers present a mixed picture. On one side, Cogent Biosciences appears relatively good value next to a peer group trading at 24.6x book, suggesting the stock is not at the highest enthusiasm levels within its niche. On the other side, a P/B of 11.5x that is far above the 2.3x industry average indicates that the market is assigning a much richer value than is typical for the wider biotech sector.

Put differently, compared with direct peers the stock looks comparatively restrained. However, compared with the broader industry it carries a premium that reflects expectations that the pipeline and forecasts around future profitability and revenue growth are worth paying up for. Investors weighing the recent loss and forecast transition to profitability may want to consider which comparison set matters more for them: nearby peers or the wider industry.

Result: Price-to-book of 11.5x (ABOUT RIGHT)

However, there are clear pressure points, including ongoing annual net losses of US$328.94 million and a P/B multiple that remains well above the wider biotech industry.

Next Steps

With sentiment clearly split between concern about ongoing losses and optimism around the pipeline, it makes sense to move quickly and pressure test the story for yourself by weighing its 1 key reward and 2 important warning signs

Looking for more investment ideas?

Cogent Biosciences might be on your radar now, but you do not want to miss other stocks that could fit your goals and risk comfort.

• Target potential mispricing by scanning a curated list of companies trading below what their fundamentals might suggest using the 48 high quality undervalued stocks.
• Prioritise resilience by focusing on businesses with lower risk scores and sturdier profiles through the 70 resilient stocks with low risk scores.
• Get ahead of the crowd by spotting underfollowed opportunities with strong fundamentals using the screener containing 25 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.